We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+29.57%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$310M
Cap. Flow
+$124M
Cap. Flow %
7.72%
Top 10 Hldgs %
66.37%
Holding
50
New
7
Increased
9
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$92.8M
2
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$25.4M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$10.7M
4
VRNA
Verona Pharma
VRNA
+$9.54M
5
KALV
KalVista Pharmaceuticals
KALV
+$8.93M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.7M
2
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
+$15.2M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$9.31M
4
PCVX icon
Vaxcyte
PCVX
+$5.89M
5
MGNX icon
MacroGenics
MGNX
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Miscellaneous 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
26
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$12.4M 0.77%
393,000
– –
MRUS
27
DELISTED
Merus
MRUS
$11.5M 0.72%
746,479
– –
VECT
28
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$11.5M 0.71%
+1,333,400
New +$10.7M
RNAM
29
DELISTED
Avidity Biosciences
RNAM
$11.1M 0.69%
+500,000
New +$7.46M
IMVT icon
30
Immunovant
IMVT
$8.51B
$10.4M 0.65%
585,759
– –
TYRA icon
31
Tyra Biosciences
TYRA
$1.49B
$10.1M 0.63%
1,327,665
– –
BLUE
32
DELISTED
bluebird bio
BLUE
$9.97M 0.62%
72,038
– –
ARVN icon
33
Arvinas
ARVN
$600M
$9.76M 0.61%
285,331
– –
PRTA icon
34
Prothena Corp
PRTA
$479M
$7.71M 0.48%
+127,900
New +$7.49M
AUTL
35
Autolus Therapeutics
AUTL
$623M
$7.12M 0.44%
3,746,857
– –
NTLA icon
36
Intellia Therapeutics
NTLA
$1.8B
$7.11M 0.44%
203,684
– –
THRX
37
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.96M 0.43%
+1,398,194
New +$8.19M
PASG icon
38
Passage Bio
PASG
$14.5M
$5.18M 0.32%
187,846
– –
ZYME icon
39
Zymeworks
ZYME
$2.02B
$4.79M 0.3%
+610,000
New +$4.29M
ACRS icon
40
Aclaris Therapeutics
ACRS
$885M
$4.57M 0.28%
290,189
-118,140
-29% -$1.9M
EPIX
41
DELISTED
ESSA Pharma
EPIX
$1.52M 0.09%
605,141
-87,769
-13% -$252K
APTX
42
DELISTED
Aptinyx Inc. Common Stock
APTX
$537K 0.03%
1,883,244
– –
NAMSW icon
43
NewAmsterdam Pharma Warrant
NAMSW
$434K 0.03%
+500,333
New +$412K
NBRV
44
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$32.2K ﹤0.01%
17,025
– –
MGNX icon
45
MacroGenics
MGNX
$263M
– –
-701,631
Closed -$2.43M
GRCL
46
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-2,890,102
Closed -$9.31M
PRDS
47
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-845,636
Closed -$1.56M
MTEM
48
DELISTED
Molecular Templates, Inc.
MTEM
– –
-91,603
Closed -$1.03M
TCDA
49
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-2,549,671
Closed -$26.7M
FLACU
50
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-1,501,000
Closed -$15.2M
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2022 Portfolio in Review

As of Q4 2022, Frazier Life Sciences Management held 50 positions worth $1.61B, up 24% from $1.3B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Frazier Life Sciences Management deployed $124M of net new capital in Q4 2022, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was NewAmsterdam Pharma: 9,341,551 shares worth $102M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $5.89M trimmed.

  • Frazier Life Sciences Management's largest Q4 2022 buy was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
  • Frazier Life Sciences Management added most to Imago BioSciences, Inc. Common stock in Q4 2022, an estimated $25.4M increase.
  • Frazier Life Sciences Management's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $5.89M.
  • Frazier Life Sciences Management fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $26.7M.
  • Frazier Life Sciences Management's ten largest holdings make up 66% of its $1.61B portfolio in Q4 2022.
  • Frazier Life Sciences Management opened 7 new positions and closed 6 in Q4 2022.
  • Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.61B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2022, filed 3 Feb 2023.